Dual Regimen Superior for Metastatic RCC
BEVACIZUMAB USED in combination with interferon alfa as a first-line treatment for metastatic renal cell carcinoma (RCC) nearly doubled progression-free survival in patients taking part in an international phase III trial.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.